Triethylamine → HCID 67621272、化合物
反応式
[NH:1]1[CH2:8][CH2:7][CH2:6][C@H:2]1[C:3]([OH:5])=O.[CH2:9]([NH:16][C:17](=[O:24])[C@H:18]([C@H:20]([CH2:22][CH3:23])[CH3:21])[NH2:19])[C:10]1[CH:15]=[CH:14][CH:13]=[CH:12][CH:11]=1.C(N(CC)CC)C.Br[CH2:33][C:34]([C:36]1[CH:41]=[CH:40][C:39]([CH3:42])=[CH:38][C:37]=1[CH3:43])=[O:35]>C1COCC1>[CH3:43][C:37]1[CH:38]=[C:39]([CH3:42])[CH:40]=[CH:41][C:36]=1[C:34](=[O:35])[CH2:33][N:1]1[CH2:8][CH2:7][CH2:6][C@H:2]1[C:3]([N:16]([CH2:9][C:10]1[CH:15]=[CH:14][CH:13]=[CH:12][CH:11]=1)[C:17](=[O:24])[C@H:18]([C@H:20]([CH2:22][CH3:23])[CH3:21])[NH2:19])=[O:5]参加物
5
実験手順
Using the procedure described in Example 5, treatment of a solution of L-proline-L-isoleucine benzylamide (60 mg, 0.19 mmol), with triethylamine (130 uL, 0.94 mmol, 5.0 eq), and 2-bromo-2',4'-dimethylacetophenone (52 mg, 0.23 mmol, 1.2 eq) in THF (7 mL), provided a crude product. A portion of the product was purified by preparative TLC to provide 19 mg (21%) of L-isoleucine, N-[1-(2-(2,4-dimethylphenyl)-2-oxoethyl)-L-prolyl] benzylamide.
後処理
- customprovided a crude product
- customA portion of the product was purified by preparative TLC
出典と根拠
- ORDレコード
- ord-5d2260a5cc324e1cbdb8280635994031
- 出典データセット
- uspto-grants-1997_11
- 特許番号
- US05686424
反応ノート
読み込み中…